GSK plc (GSK) Form 6-K — Oct 19, 2026
GSK reported first global data for Ris-Rez, its B7-H3-targeted antibody-drug conjugate, in relapsed extensive-stage small cell lung cancer. The phase Ib dose-optimisation portion of the EMBOLD PanTumour-101 trial showed a 61% confirmed objective response rate at the 8 mg/kg dose versus 32% at 6 mg/kg. Safety was manageable at a median follow-up of 100.5 days, with grade 3+ treatment-related adverse events in 42% of 8 mg/kg patients and interstitial lung disease in just 1 of 50 patients. The data support the 8 mg/kg dose selected for the ongoing global phase III EMBOLD SCLC-301 study.
Key figures
- Ild rate
- 2% (1/50 patients, grade 2)
- Orr 6mgkg
- 32% (n=7/22; 95% CI: 13.9-54.9)
- Orr 8mgkg
- 61% (n=11/18; 95% CI: 35.7-82.7)
- Patients analyzed
- 50
- Median followup days
- 100.5
- Grade3plus trae 6mgkg
- 15%
- Grade3plus trae 8mgkg
- 42%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.